2026-10-12 18:37:00 UTC#448326newconfirmednews
Insulet (PODD) stock news
Insulet (PODD) stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-07 12:59:00 UTC#425819newconfirmednews
Barclays sets $150.00 price target on Insulet Corporation (PODD)
2026-09-24 17:42:10 UTC#364482newconfirmednews
Insulet (PODD) reports Q2 growth driven by international expansion and 40% new starts from type 2 diabetes segment
2026-09-21 21:13:01 UTC#345274duplicateconfirmednews
Insulet Corporation refinances $475M term loans and expands revolving credit facility to $750M
2026-09-21 21:06:12 UTC#345210newconfirmednews
Insulet Corporation amends credit agreement, replaces $475M in term loans with lower-rate debt and adds $250M revolver
2026-08-06 20:54:00 UTC#140355newconfirmednews
Leerink Partners cuts Insulet price target to $145 from $247
2026-08-06 19:57:00 UTC#139942newconfirmednews
TD Cowen maintains Hold on Insulet, slashes price target to $144 from $294
2026-08-06 19:10:00 UTC#139669newconfirmednews
UBS maintains Neutral rating on Insulet
2026-08-06 17:40:00 UTC#139208newconfirmednews
RBC Capital maintains Outperform rating on Insulet
2026-08-06 16:55:00 UTC#138965newconfirmednews
Bernstein maintains Outperform rating on Insulet, cuts price target to $175 from $200
2026-08-06 15:44:00 UTC#138558newconfirmednews
Benchmark maintains Buy rating on Insulet, cuts price target to $185 from $250
2026-08-05 18:52:15 UTC#132045newconfirmednews
Insulet downgraded at Oppenheimer citing increasing risks
2026-08-05 18:21:01 UTC#131909duplicateconfirmednews
Insulet reiterates 2026 revenue growth guidance of 20%-22% following U.S. type 2 retention adjustments
2026-08-05 16:17:00 UTC#131270updateconfirmednews
Insulet shares drop 19% to worst day since 2009 despite Q2 earnings beat
2026-08-05 14:44:32 UTC#130698updateconfirmednews
Insulet guidance cut triggers share price declines for peers Tandem and DexCom
seeking alphaimportance 0.40trust 0.70Insulet Corporation -0.40Tandem Diabetes Care, Inc. -0.30DexCom, Inc. -0.30
2026-08-05 13:31:36 UTC#130322duplicateconfirmednews
Insulet Corporation Q2 adjusted EPS $1.37 misses $1.45 estimate, revenue $801.7M beats
2026-08-05 13:30:40 UTC#130363updateconfirmednews
Insulet (PODD) cites type 2 diabetes patient retention challenges as primary driver for 2026 outlook revision
2026-08-05 12:01:17 UTC#129578updateconfirmednews
Insulet cuts 2026 revenue growth forecast to 20-22% on weaker US Omnipod demand
2026-08-05 11:57:46 UTC#129717duplicateconfirmednews
Insulet (PODD) Q2 2026 revenue grows 23.5% with 41.5% adjusted EPS growth, reaffirms FY 2026 outlook
2026-08-05 11:15:44 UTC#129323duplicateconfirmednews